GRI Bio Files Definitive Proxy Statement

TL;DR

GRI Bio filed its proxy statement, shareholders vote soon.

AI Summary

GRI Bio, Inc. filed a definitive proxy statement (DEF 14A) on January 17, 2025, for its fiscal year ending December 31, 2024. The company, formerly known as Vallon Pharmaceuticals, Inc. until April 24, 2023, is based in La Jolla, California, and operates in the pharmaceutical preparations sector. The filing is related to the Securities Exchange Act of 1934.

Why It Matters

This filing provides shareholders with essential information regarding company governance and upcoming decisions, allowing them to exercise their voting rights effectively.

Risk Assessment

Risk Level: low — This is a routine regulatory filing for a public company and does not inherently present new risks.

Key Players & Entities

• GRI Bio, Inc. (company) — Registrant
• Vallon Pharmaceuticals, Inc. (company) — Former company name
• 20250117 (date) — Filing date
• 20250211 (date) — Period of report
• 1934 Act (legal_document) — Securities Exchange Act

FAQ

Key Financial Figures

• $8,500 — e and information support, for a fee of $8,500, plus reasonable expenses. What does i
• $1.00 — shares of our common stock of at least $1.00 per share (also referred to as the "min
• $0.10 — common stock has a closing bid price of $0.10 per share or less for ten consecutive t
• $1.00 b — mon stock will remain above the minimum $1.00 bid price required for any post-split Nas

Filing Documents

• gridefinitiveproxystatemen.htm (DEF 14A) — 165KB
• image_0a.jpg (GRAPHIC) — 24KB
• proxycard1.jpg (GRAPHIC) — 100KB
• proxycard2.jpg (GRAPHIC) — 106KB
• 0001824293-25-000011.txt ( ) — 483KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 14

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 14 ADDITIONAL INFORMATION 14 APPENDIX A Appendix A- 1 APPENDIX B Appendix B- 1 i 2223 Avenida de la Playa, Suite 208 La Jolla, CA 92037 PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS TO BE HELD ON FEBRUARY 11, 2025 This proxy statement (the "Proxy Statement") is furnished to stockholders of GRI Bio, Inc., a Delaware corporation (the "Company," "we," "us," or "our"), in connection with the solicitation of proxies by our board of directors for use at a special meeting of stockholders to be held on February 11, 2025, and at any adjournment or postponement thereof (our "Special Meeting"). Our Special Meeting will be held at 900 a.m. Eastern time via a live audio webcast at www.virtualshareholdermeeting.comGRI2025SM. On or about January 17, 2025, we will commence mailing of the proxy materials which are also available at www.proxyvote.com. The proxy materials are being sent to stockholders who owned our common stock at the close of business on January 6, 2025, the record date for the Special Meeting (the "Record Date"). This Proxy Statement contains important information for you to consider when deciding how to vote on the matters brought before the meeting. Please read it carefully. Why am I receiving these materials We sent you this Proxy Statement because our board of directors is soliciting your proxy to vote at our Special Meeting. This Proxy Statement summarizes the information you need to vote at our Special Meeting. You do not need to attend our Special Meeting to vote your shares. What proposals will be voted on at the Special Meeting Stockholders will vote on two proposals at the Special Meeting 1. The approval of an amendment to our Amended and Restated Certificate of Incorporation, as amended (the "Amended and Restated Certificate of Incorporation"), to effect a reverse stock split of our common stock by a ratio of not less than one-for-two and not more than one-for-2

View Full Filing

View this DEF 14A filing on SEC EDGAR